Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Trilaciclib||G1T28||CDK4/6 Inhibitor 9||Trilaciclib (G1T28) is a small molecule that inhibits CDK4/6, resulting in reversible cell-cycle arrest, and potentially reduces myelosuppression induced by chemotherapeutics (PMID: 26826116).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|RB1 loss||lung small cell carcinoma||resistant||Trilaciclib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to Trilaciclib (G1T28) in culture and in xenograft models (PMID: 26826116).||26826116|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02514447||Phase Ib/II||Trilaciclib Topotecan||Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy||Active, not recruiting|
|NCT02499770||Phase Ib/II||Carboplatin + Etoposide Trilaciclib||G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)||Completed|